Director/PDMR Shareholding

RNS Number : 7266Y
Hikma Pharmaceuticals Plc
19 May 2016
 

 

Hikma Pharmaceuticals PLC - Vesting of 2013 LTIP

 

LONDON, 19 May 2016: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") announces that the following Directors and Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 17 May 2016 under the 2005 Long Term Incentive Plan ("LTIP") which was completed on 19 May 2016. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil. As indicated in the table below, certain PDMRs have made disposals.

 

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over Hikma's Ordinary Shares of 10p each ("Shares") as detailed below.

 

PDMR

Type of Transaction

Shares Acquired under LTIP

Date

Price

Shares Disposed

Remaining Holding

Said Darwazah

Vesting of LTIP 2013

88,383

(0.04% ISC)

19 May 2016

N/A

Nil

13,265,884*

(5.54% ISC)

Mazen Darwazah

Vesting of LTIP 2013

45,924

(0.02% ISC)

19 May 2016

N/A

Nil

7,256,131*

(3.03% ISC)

Bassam Kanaan

 

Vesting of LTIP 2013 & Disposal

34,660

(0.01% ISC)

19 May 2016

£22.42

34,660

418,658

(0.19% ISC)

Michael Raya

 

Vesting of LTIP 2013 & Disposal

32,927

(0.01% ISC)

19 May 2016

£22.42

19,047

133,840

(0.06% ISC)

Riad Mishlawi

Vesting of LTIP 2013

19,063

(0.01% ISC)

 

19 May 2016

N/A

Nil

119,090

(0.05% ISC)

Khalid Nabilsi

Vesting of LTIP 2013

19,063

(0.01% ISC)

 

19 May 2016

N/A

Nil

221,921

(0.09% ISC)

Majda Labadi

Vesting of LTIP 2013

14,848

(0.01% ISC)

 

19 May 2016

N/A

Nil

187,431

(0.08% ISC)

 

"ISC" = Issued Share Capital of Hikma which is 239,385,501 Shares following the release of the LTIP 2013.

 

* Said Darwazah has a direct interest in Hikma of 745,383 Shares and an effective interest in Hikma through his interest in Darhold Limited of 12,520,501 Shares. Mazen Darwazah has a direct interest in Hikma of 952,965 Shares and an effective interest in Hikma through his interest in Darhold Limited of 6,303,166 Shares.

 

 

- ENDS -

 

Enquiries                                                                                                                                      

Peter Speirs                                                                          +44 20 7399 2760

Company Secretary, Hikma Pharmaceuticals PLC

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGCGDUSBBBGLC
UK 100

Latest directors dealings